Related Experiment Videos
Prostate-specific antigen as a marker of prostate disease
R Montironi1, R Mazzucchelli, F Algaba
1Institute of Pathological Anatomy, University of Ancona School of Medicine, Torrette, Italy. r.montironi@popcsi.unian.it
Summary
Serum prostate-specific antigen (PSA) testing has transformed prostate cancer (PCa) management, aiding early detection, staging, and patient monitoring. This marker is crucial for assessing disease extent and treatment effectiveness.
Area of Science:
- Oncology
- Urology
- Biochemistry
Background:
- Prostate cancer (PCa) management has been significantly advanced by serum prostate markers.
- Prostate-specific antigen (PSA) is a key biomarker in this field.
Purpose of the Study:
- To highlight the revolutionary impact of PSA in PCa management.
- To emphasize the utility of PSA in early detection, screening, and staging.
- To underscore PSA's role in monitoring treatment response.
Main Methods:
- Review of clinical utility studies on serum PSA levels.
- Analysis of PSA association with other diagnostic parameters (e.g., tumor grade, DRE, TRUS).
- Evaluation of PSA's role in post-diagnosis and post-therapy monitoring.
Main Results:
- PSA has revolutionized early detection and screening for PCa.
- PSA levels, combined with other parameters, improve the likelihood of assessing disease extension and lymph node involvement.
- Serum PSA is valuable for monitoring PCa patients after diagnosis and therapy.
Conclusions:
- Serum PSA is an indispensable tool in modern prostate cancer management.
- PSA facilitates comprehensive patient assessment from diagnosis through treatment monitoring.
- The clinical utility of PSA extends across screening, staging, and therapeutic evaluation.